TAXOTERE

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Commercializzato da:

SANOFI - AVENTIS ISRAEL LTD

Codice ATC:

L01CD02

Forma farmaceutica:

CONCENTRATE FOR SOLUTION FOR INFUSION

Via di somministrazione:

I.V

Prodotto da:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Gruppo terapeutico:

DOCETAXEL

Indicazioni terapeutiche:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Data dell'autorizzazione:

2012-11-01